Solid Biosciences reports Q3 2026 earnings and issues business update

Solid Biosciences reports Q3 2026 earnings and issues business update
Solid Biosciences Q3 2026 earnings

Solid Biosciences announced its earnings results for the third quarter of 2026 and provided a business update.

The company released a press statement outlining its financial performance and recent activities. No further specifics on the results were disclosed in the tweet.

Earlier this month, Solid Biosciences announced plans to present seven posters featuring advances in Duchenne therapies and platform technologies at ESGCT2026, according to a company update. The firm previously secured European Orphan designation for its SGT-212 candidate and reported dosing of five patients in the FALCON trial, as detailed in recent statements. Both announcements highlight ongoing clinical and regulatory progress.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.